drugset / Trial / NCT05023343

Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

NCT05023343 ↗

Phase 4 Completed 20 enrolled Zealand University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.

Timeline

Start
2021-10-02
Primary completion
2021-11-28
Completion
2021-11-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ropivacaine Other / unclassified 0.75 % Other
Comparator Ropivacaine Other / unclassified 30 ml Other

Indications

No indication recorded.